Helicobacter pylori infection
Conditions
Interventions
Trial Group:Olympus (containing IgY antibody): Twice daily, 2 bottles (3g/bottle) each time, dissolved in warm water below 40? after meals, consumed orally for 14 consecutive days. (15 cases in the pr
Control Group:Special Medical Purpose Hydrolyzed Whey Protein Powder: Twice daily, 2 bottles (3g/bottle) each time, dissolved in warm water below 40? after meals, consumed orally for 14 consecutive da
Sponsors
Wenzhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participates in this clinical trial and is capable of understanding and signing the informed consent form; 2. Aged 18–70 years (inclusive), of either sex, and treatment-naïve; 3. Positive 13C-urea breath test confirming Helicobacter pylori (H. pylori) infection; 4. Serologically confirmed as a Type I H. pylori-infected individual; 5. Able to abstain from smoking and alcohol consumption during the trial.
Exclusion criteria
Exclusion criteria: 1. Individuals allergic to egg products and dairy products (including lactose); 2. Individuals with a history of esophageal or gastrointestinal surgery (appendectomy excluded); 3. Individuals with severe impairment of cardiac, hepatic, or renal function; 4. Individuals with organic gastrointestinal disorders, including gastrointestinal tumors, gastrointestinal bleeding, perforation, or pyloric obstruction; 5. Individuals who have taken antibiotics, bismuth agents, or traditional Chinese medicine within the past 4 weeks, or proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs), or probiotics within the past 2 weeks; 6. Pregnant or lactating women; 7. Individuals with psychiatric disorders that may impede cooperation; 8. Individuals with alcohol or substance abuse; 9. Individuals who do not meet the study eligibility criteria or whom the investigators deem unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response rate (eradication + improvement); | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastrointestinal symptom score improvement;Rate of DOB value reduction; | — |
Countries
China
Contacts
Public ContactPan Jie
Wenzhou Central Hospital
Outcome results
None listed